Elacestrant组合疗法显示,在新的试验数据中,ER-阳性、HER2-阴性乳腺癌有希望。 Elacestrant combo therapy shows promise for ER-positive, HER2-negative breast cancer in new trial data.

在2025年圣安东尼奥乳腺癌研讨会上,Menarini Group分享了新的一期2期试验数据,该试验数据是关于elacestrant (ORSERDU®) 与其他治疗方法结合用于ER阳性,HER2阴性转移性乳腺癌患者,显示了疾病控制和无进展生存的有希望的结果,尽管具体的数值结果在摘要中没有详细说明. At the 2025 San Antonio Breast Cancer Symposium, Menarini Group shared new Phase 2 trial data on elacestrant (ORSERDU®) combined with other treatments for patients with ER-positive, HER2-negative metastatic breast cancer, showing promising results in disease control and progression-free survival, though specific numerical outcomes were not detailed in the summary.